US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
US6114110A
(en)
*
|
1996-01-16 |
2000-09-05 |
University Of Michigan |
Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
|
US20030103984A1
(en)
*
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
ATE267215T1
(de)
|
1997-12-08 |
2004-06-15 |
Lexigen Pharm Corp |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
EP1042459A4
(en)
*
|
1997-12-24 |
2003-07-23 |
Diatech Pty Ltd |
BIFUNCTIONAL MOLECULES
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
JP2002511432A
(ja)
*
|
1998-04-15 |
2002-04-16 |
レキシジェン ファーマシューティカルズ コーポレイション |
新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
CA2343094A1
(en)
*
|
1998-10-16 |
2000-04-27 |
Biogen, Inc. |
Interferon-beta fusion proteins and uses
|
EP1739090A3
(en)
*
|
1998-10-16 |
2009-04-08 |
Biogen Idec MA Inc. |
Interferon-beta fusion proteins and uses
|
EE05201B1
(et)
*
|
1998-10-16 |
2009-08-17 |
Biogen Idec Ma Inc. |
Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6913749B2
(en)
*
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
BR0010725A
(pt)
*
|
1999-05-19 |
2002-02-19 |
Lexigen Pharm Corp |
Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
|
WO2001004304A1
(en)
|
1999-07-07 |
2001-01-18 |
Zymogenetics, Inc. |
Human cytokine receptor
|
AU782496B2
(en)
*
|
1999-07-13 |
2005-08-04 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
HUP0202442A3
(en)
*
|
1999-08-09 |
2005-01-28 |
Lexigen Pharmaceuticals Corp L |
Multiple cytokine-antibody complexes
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
AU2001226935B2
(en)
*
|
2000-01-24 |
2006-06-22 |
Gendaq Limited |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
ATE336514T1
(de)
*
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
PT1294401E
(pt)
*
|
2000-06-29 |
2007-11-09 |
Merck Patent Gmbh |
Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
|
US20020169290A1
(en)
*
|
2000-11-02 |
2002-11-14 |
Claus Bornaes |
New multimeric interferon beta polypeptides
|
WO2002036628A2
(en)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
New multimeric interferon beta polypeptides
|
CN1610754B
(zh)
*
|
2000-12-01 |
2012-07-04 |
维莱尼姆公司 |
具有脱卤素酶活性的酶及其使用方法
|
ES2727425T3
(es)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7141392B2
(en)
*
|
2001-01-09 |
2006-11-28 |
Queen Mary And Westfield College |
Latent fusion protein
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
FR2821625B1
(fr)
*
|
2001-03-01 |
2003-05-16 |
Genodyssee |
Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
|
EP1370676A4
(en)
|
2001-03-02 |
2004-09-22 |
Zymogenetics Inc |
CYTOKIN RECEPTOR FROM MOUSE
|
US20030068320A1
(en)
*
|
2001-03-02 |
2003-04-10 |
Christine Dingivan |
Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
KR20090010127A
(ko)
*
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
|
CN1191271C
(zh)
*
|
2001-03-21 |
2005-03-02 |
中国科学院上海生物化学研究所 |
干扰素-胸腺肽融合蛋白及其制法
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
FR2823220B1
(fr)
*
|
2001-04-04 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
|
DK1383785T3
(da)
*
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
US20030059811A1
(en)
*
|
2001-06-14 |
2003-03-27 |
Hakim Djaballah |
Methods of screening for ligands of target molecules
|
US6962982B2
(en)
*
|
2001-06-22 |
2005-11-08 |
Roche Diagnostics Corporation |
Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
|
US7094757B2
(en)
*
|
2001-06-22 |
2006-08-22 |
Roche Diagnostics Corporation |
Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
|
ATE522603T1
(de)
*
|
2001-06-22 |
2011-09-15 |
Hoffmann La Roche |
Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
|
WO2003005964A2
(en)
*
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
US20030104604A1
(en)
*
|
2001-08-03 |
2003-06-05 |
Weiping Yang |
Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
|
CN101200503B
(zh)
*
|
2001-08-10 |
2010-07-07 |
中国人民解放军军事医学科学院生物工程研究所 |
血清白蛋白与干扰素的融合蛋白
|
US6900292B2
(en)
*
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6797493B2
(en)
*
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
ATE542137T1
(de)
*
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
BR0307907A2
(pt)
*
|
2002-02-21 |
2011-07-05 |
Wyeth Corp |
gasp1: proteìna contendo domìnio de folistatina
|
JP4429728B2
(ja)
*
|
2002-02-21 |
2010-03-10 |
ワイス エルエルシー |
フォリスタチン(follistatin)ドメイン含有タンパク質
|
EP1572936A2
(en)
*
|
2002-03-05 |
2005-09-14 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
JP4883665B2
(ja)
*
|
2002-07-17 |
2012-02-22 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
インターフェロン−βを使用する腎不全のための治療法
|
CA2497628A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
JP4547561B2
(ja)
*
|
2002-09-16 |
2010-09-22 |
ザ ジョンズ ホプキンス ユニバーシティー |
メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法
|
KR101388611B1
(ko)
|
2002-10-16 |
2014-04-23 |
퍼듀 퍼머 엘피 |
세포-연관된 ca 125/o772p에 결합하는 항체들 및 그것의 용도의 방법들
|
US7261893B2
(en)
*
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
WO2004055056A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
PL376673A1
(pl)
*
|
2003-02-18 |
2006-01-09 |
Merck Patent Gmbh |
Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach
|
EP1613342A1
(en)
*
|
2003-04-17 |
2006-01-11 |
Ares Trading S.A. |
Interferon beta in severe acute respiratory syndrome (sars)
|
CN1535724B
(zh)
*
|
2003-04-23 |
2012-09-05 |
北京金迪克生物技术研究所 |
重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
ES2361036T3
(es)
*
|
2003-05-06 |
2011-06-13 |
Syntonix Pharmaceuticals, Inc. |
Proteínas quiméricas vii-fc del factor de coagulación para el tratamiento de un trastorno hemostático.
|
US20050037947A1
(en)
*
|
2003-05-06 |
2005-02-17 |
Bitonti Alan J. |
Inhibition of drug binding to serum albumin
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
US7785587B2
(en)
*
|
2003-06-02 |
2010-08-31 |
Wyeth |
Therapeutic methods for muscular or neuromuscular disorders
|
US7452966B2
(en)
*
|
2003-06-12 |
2008-11-18 |
Eli Lilly And Company |
GLP-1 analog fusion proteins
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
DK2256134T3
(en)
|
2003-11-13 |
2014-02-24 |
Hanmi Science Co Ltd |
IgG Fc fragment to a drug carrier and process for preparation thereof
|
DE602004013372T2
(de)
|
2003-12-30 |
2009-07-02 |
Merck Patent Gmbh |
Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
|
RU2370276C2
(ru)
*
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
ES2330860T3
(es)
|
2004-01-22 |
2009-12-16 |
Merck Patent Gmbh |
Anticuerpos anticancerosos con fijacion del complemento reducida.
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
EP1778275A2
(en)
*
|
2004-08-12 |
2007-05-02 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
US20090249503A1
(en)
*
|
2004-12-06 |
2009-10-01 |
Bolder Biotechnology, Inc. |
Enzyme conjugates for use as detoxifying agents
|
CN101072793B
(zh)
*
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
WO2006086396A2
(en)
|
2005-02-08 |
2006-08-17 |
Zymogenetics, Inc. |
Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
CA2601086A1
(en)
*
|
2005-03-23 |
2006-10-12 |
Wyeth |
Detection of an immune response to gdf-8 modulating agents
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
WO2006124667A2
(en)
|
2005-05-12 |
2006-11-23 |
Zymogenetics, Inc. |
Compositions and methods for modulating immune responses
|
EP1899368A2
(en)
*
|
2005-05-26 |
2008-03-19 |
Schering Corporation |
Interferon-igg fusion
|
WO2007021129A1
(en)
*
|
2005-08-16 |
2007-02-22 |
Hanmi Pharmaceutical Co., Ltd. |
A method for the mass production of immunoglobulin fc region deleted initial methionine residues
|
CN101282740A
(zh)
|
2005-09-01 |
2008-10-08 |
阿雷斯贸易股份有限公司 |
视神经炎的治疗
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
PT1966238E
(pt)
|
2005-12-30 |
2012-07-31 |
Merck Patent Gmbh |
Uso de hsp70 como um regulador de atividade enzimática
|
KR101397290B1
(ko)
*
|
2005-12-30 |
2014-05-21 |
메르크 파텐트 게엠베하 |
감소한 면역원성을 가지는 항-cd19 항체
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US8592149B2
(en)
|
2006-04-27 |
2013-11-26 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
PL2026832T3
(pl)
|
2006-05-24 |
2012-08-31 |
Merck Serono Sa |
Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego
|
AR061930A1
(es)
*
|
2006-07-18 |
2008-10-01 |
Centocor Inc |
Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
|
EP2292663B1
(en)
|
2006-08-28 |
2013-10-02 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
WO2008057529A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Coley Pharmaceutical Group, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
|
KR100888022B1
(ko)
*
|
2006-12-21 |
2009-03-09 |
재단법인 목암생명공학연구소 |
면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
US7625555B2
(en)
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
WO2009012600A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
EP2200634B1
(en)
|
2007-09-21 |
2015-02-11 |
The Regents of The University of California |
Targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2602263B1
(en)
|
2007-11-21 |
2019-07-17 |
Roskilde Universitet |
Polypeptides comprising an ice-binding activity
|
WO2009080054A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Ifxa A/S |
Protease inhibitor
|
NZ600205A
(en)
*
|
2008-01-25 |
2013-12-20 |
Univ Aarhus |
Selective exosite inhibition of papp-a activity against igfbp-4
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
RU2483081C2
(ru)
|
2008-07-23 |
2013-05-27 |
Ханми Сайенс Ко.,Лтд.,Kr |
Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
|
EP2323679A4
(en)
|
2008-07-25 |
2012-08-22 |
Univ Colorado |
CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION
|
EA201171259A1
(ru)
*
|
2009-04-22 |
2012-05-30 |
Мерк Патент Гмбх |
Антительные гибридные белки с модифицированными сайтами связывания fcrn
|
ES2548030T3
(es)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Moléculas con semividas prolongadas y usos de las mismas
|
AU2010282340B2
(en)
|
2009-08-13 |
2016-12-22 |
The Johns Hopkins University |
Methods of modulating immune function
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
KR101340710B1
(ko)
*
|
2010-01-19 |
2013-12-12 |
한미사이언스 주식회사 |
지속형 과립구 콜로니 자극인자 결합체의 액상 제제
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
US20110243942A1
(en)
*
|
2010-04-02 |
2011-10-06 |
Athena Discovery, Inc. |
Relaxin-fusion proteins with extended in vivo half-lives
|
EP2558482B1
(en)
|
2010-04-16 |
2017-09-27 |
Janssen Biotech, Inc. |
Engineered plant cysteine proteases and their uses
|
MX356527B
(es)
|
2010-07-09 |
2018-06-01 |
Bioverativ Therapeutics Inc |
Polipeptidos de factor ix y metodos para usarlos.
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
CN102585013B
(zh)
*
|
2011-01-07 |
2014-04-23 |
中国人民解放军军事医学科学院生物工程研究所 |
一种含有ω干扰素的融合蛋白及制备方法
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
CN102212139A
(zh)
*
|
2011-03-29 |
2011-10-12 |
中国人民解放军第二军医大学 |
森林脑炎病毒包膜E蛋白与人抗体Fc段融合蛋白及其用途
|
CN103717614A
(zh)
*
|
2011-08-09 |
2014-04-09 |
普罗法尔马封闭式股份公司 |
重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
|
ES2942483T3
(es)
|
2011-10-05 |
2023-06-01 |
Oned Mat Inc |
Materiales activos de nanoestructuras de silicio para baterías de iones de litio y procesos, composiciones, componentes y dispositivos relacionados con los mismos
|
CA2851892C
(en)
|
2011-10-28 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
EP3290442A1
(en)
|
2011-11-04 |
2018-03-07 |
Novartis AG |
Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
|
CN105001340A
(zh)
*
|
2012-01-19 |
2015-10-28 |
施怀哲维克有限公司 |
动物融合重组型干扰素
|
TWI492952B
(zh)
*
|
2012-01-20 |
2015-07-21 |
Sbc Virbac Ltd |
動物融合重組型干擾素
|
ES2671631T3
(es)
|
2012-04-23 |
2018-06-07 |
Nrl Pharma, Inc. |
Proteína de fusión de lactoferrina y método para la preparación de la misma
|
CN103044554B
(zh)
*
|
2012-05-14 |
2014-08-27 |
旭华(上海)生物研发中心有限公司 |
重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
|
US9498538B2
(en)
|
2012-05-21 |
2016-11-22 |
Massachusetts Institute Of Technology |
Translocation of non-natural chemical entities through anthrax protective antigen pore
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
BR112014032276A2
(pt)
*
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
EP4063391A1
(en)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
CN105246507B
(zh)
|
2012-09-07 |
2019-01-25 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
JP2016511747A
(ja)
|
2013-01-04 |
2016-04-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
ナノ粒子表面結合に基づく薬物の組織への送達
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
FI3677591T3
(fi)
|
2013-04-29 |
2023-04-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
EP3041507B1
(en)
|
2013-08-26 |
2021-06-30 |
BioNTech Research and Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
SG11201606018UA
(en)
|
2014-01-24 |
2016-08-30 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
WO2015161832A1
(zh)
*
|
2014-04-25 |
2015-10-29 |
辅仁药业集团有限公司 |
长效重组人干扰素α2b-Fc融合蛋白
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
CN106459960A
(zh)
|
2014-05-13 |
2017-02-22 |
生物蛋白有限公司 |
条件活性生物蛋白
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
US9856324B2
(en)
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
AU2015311911B2
(en)
|
2014-09-03 |
2019-01-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
KR102639037B1
(ko)
|
2014-10-29 |
2024-02-20 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
인터페론 α2b 변이체
|
CN104403004B
(zh)
*
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
PL3800202T3
(pl)
|
2014-12-11 |
2023-06-12 |
Pierre Fabre Medicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
EP3265123B1
(en)
|
2015-03-03 |
2022-10-26 |
Kymab Limited |
Antibodies, uses & methods
|
MA42059A
(fr)
|
2015-05-06 |
2018-03-14 |
Janssen Biotech Inc |
Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
EP3341391A4
(en)
|
2015-08-27 |
2019-03-06 |
President and Fellows of Harvard College |
COMPOSITIONS AND METHODS OF PAIN TREATMENT
|
TW201718629A
(zh)
*
|
2015-09-25 |
2017-06-01 |
韓美藥品股份有限公司 |
包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
KR20180064534A
(ko)
|
2015-11-02 |
2018-06-14 |
바이오아트라, 엘엘씨 |
조건부 활성 폴리펩티드
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
MA44776A
(fr)
|
2016-04-15 |
2019-03-06 |
Immunext Inc |
Anticorps anti-vista humain et leur utilisation
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
CN110114460A
(zh)
|
2016-10-28 |
2019-08-09 |
Nrl制药股份有限公司 |
乳铁蛋白/白蛋白融合蛋白质及其制备方法
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
US20210023236A1
(en)
*
|
2019-07-26 |
2021-01-28 |
Massachusetts Institute Of Technology |
Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
|
EP4047016A1
(en)
|
2021-02-19 |
2022-08-24 |
Université de Strasbourg |
Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof
|
AR128222A1
(es)
|
2022-01-07 |
2024-04-10 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|